Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA9 | Q16790 | 2/20 | 0.74 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393962 | 0.85 | CA12 (1.00) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL8515316 | 0.85 | CA12 (1.00) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL3492605 | 0.81 | KCNA3 (0.69) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL3911837 | 0.81 | KCNA3 (0.69) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL6592785 | 0.81 | KCNA3 (0.69) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL3912517 | 0.79 | KCNA3 (0.72) | CA12CA1CA9KCNA3MAOB | |
| Hydrochloric Acid SCHEMBL31460826 | 0.79 | KCNA3 (0.68) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL6599915 | 0.79 | KCNA3 (0.72) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL24523000 | 0.78 | KCNA3 (0.70) | CA12CA1CA9KCNA3MAOB | |
| SCHEMBL6588939 | 0.78 | KCNA3 (0.74) | CA12CA1CA9KCNA3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | claimed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | CA12 3287/4885CA1 934/4885CA9 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.